LDS/Medical Tests/FoundationOne®CDx (F1CDx) and FoundationOne® Liquid CDx

FoundationOne®CDx (F1CDx) and FoundationOne® Liquid CDx

FoundationOne®CDx (F1CDx) is a next generation sequencing based in vitro diagnostic method for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes, select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB). The testing is performed using DNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in Table 1 in accordance with the approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling for patients with solid malignant neoplasms. Product claims are as follow:

For Non-Small Cell Lung Cancer (NSCLC), these mutations are relevant and related to therapy selection

  • EGFR exon 19 deletions & EGFR exon 21 L858R alterations
  • EGFR exon 20 T790M alterations
  • ALK rearrangements
  • BRAF V600E

FDA approved therapy selection based on mutation detection

  • Gilotrif® (afatinib), Iressa® (gefitinib), Tagrisso® (osimertinib), or Tarceva® (erlotinib)
  • Tagrisso® (osimertinib)
  • Alecensa® (alectinib), Xalkori® (crizotinib) or Zykadia® (ceritinib)
  • Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib)

For Melanoma, these mutations are relevant and related to therapy selection

  • BRAF V600E
  • BRAF V600E or V600K

FDA approved therapy

  • Tafinlar® (dabrafenib) or Zelboraf® (vemurafenib)
  • Mekinist® (trametinib) or Cotellic® (cobimetinib), in combination with Zelboraf® (vemurafenib)

For Breast Cancer, these mutations are relevant and related to therapy selection

  • ERBB2 (HER2) amplification
  • PIK3CA alterations

FDA approved therapy

  • Herceptin® (trastuzumab), Kadcyla® (ado-trastuzumab-emtansine), or Perjeta® (pertuzumab)
  • Piqray® (alpelisib)

For Colorectal Cancer, these mutations are relevant and related to therapy selection

  • KRAS wild-type (absence of mutations in codons 12 and 13)
  • KRAS wild-type (absence of mutations in exons 2, 3, and 4) and NRAS wild type (absence of mutations in exons 2, 3, and 4)FDA approved thereapy
  • Erbitux® (cetuximab)
  • Vectibix® (panitumumab)

For Ovarian Cancer, these mutations are relevant and related to therapy selection

  • RAS wild-type (absence of mutations in codons 12 and 13)
  • KRAS wild-type (absence of mutations in exons 2, 3, and 4) and NRAS wild type (absence of mutations in exons 2, 3, and 4)

FDA approved therapy

  • Erbitux® (cetuximab)
  • Vectibix® (panitumumab)
  • Companion diagnostic test in non-small cell lung cancer with EGFR, ALK, BRAF mutations for treatment with Gilotrif®, Iressa®, Tagrisso®, or Tarceva®
  • Companion diagnostic test in melanoma with BRAF mutation and for treatment with Tafinlar® or Zelboraf®
  • Companion diagnostic test in Breast cancer with ERBB2 (HER2) amplification and for treatment with Herceptin®, Kadcyla® or Perjeta®
  • Companion diagnostic test for colorectal cancer with KRAS wild-type (absence of mutations in codons 12 and 13) in treatment with Erbitux® (cetuximab)
  • Companion diagnostic test for Ovarian cancer with BRCA1/2 alterations for treatment with Lynparza® (olaparib) or Rubraca® (rucaparib)
  • In cancers stage III metastatic, recurrent, relapsed, or refractory cancers, in addition to the Stage IV relapsed or refractory cancers when searching better therapy as well as cancers that previous testing did not elucidate treatment solution and disease management
All pathogenic variants and insertions/deletions will have clinical interpretation.

No reportable variants were identified (Negative for mutation analyzed)

Next Generation Sequencing (NGS).

Formalin-fixed paraffin embedded (FFPE) tumor tissue specimens, whole blood for liquid biopsy.

Breast biopsy, skin biopsy, colon biopsy.
2-3 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login